<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2182-2395</journal-id>
<journal-title><![CDATA[Revista da Sociedade Portuguesa de Dermatologia e Venereologia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Soc Port Dermatol Venereol]]></abbrev-journal-title>
<issn>2182-2395</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Dermatologia e Venereologia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2182-23952021000300021</article-id>
<article-id pub-id-type="doi">10.29021/spdv.79.3.1336</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Evaluation of Combination of Microneedling with Tacrolimus in the Treatment of Stable Vitiligo]]></article-title>
<article-title xml:lang="pt"><![CDATA[Avaliação da Combinação de Microagulhamento com Tacrolimus no Tratamento de Vitiligo Estável]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[Saurabh]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Matharoo]]></surname>
<given-names><![CDATA[Parwaaz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bassi]]></surname>
<given-names><![CDATA[Roopam]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Sri Guru Ram Das Institute of Medical Sciences &amp; Research Department of Dermatology, Venereology &amp; Leprosy ]]></institution>
<addr-line><![CDATA[Amritsar Punjab]]></addr-line>
<country>India</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Sri Guru Ram Das Institute of Medical Sciences &amp; Research Department of Physiology ]]></institution>
<addr-line><![CDATA[Amritsar Punjab]]></addr-line>
<country>India</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>09</month>
<year>2021</year>
</pub-date>
<volume>79</volume>
<numero>3</numero>
<fpage>21</fpage>
<lpage>25</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2182-23952021000300021&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2182-23952021000300021&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2182-23952021000300021&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Vitiligo is an amelanotic disorder that can manifest as localized patches to near total body depigmentation. It is considered a cosmetic disease but it is accompanied by extensive psychological effects. Multiple treatments have been tried until now but no single method has achieved the desired response. Tacrolimus is frequently used for vitiligo treatment with few adverse effects. Microneedling is a newer modality of therapeutic wounding that augments drug absorption. Combination of microneedling and tacrolimus have been tried to improve the repigmentation response in vitiligo. Our objective was to assess the safety and efficacy of this combined modality.  Methods:  Forty patients were subjected to combination of tacrolimus 0.1% ointment and microneedling at 2 week intervals for maximum 10 sessions with a follow-up period of 6 months. Assessment was based on grading of repigmentation and clinical improvement according to vitiligo noticeability scale.  Results:  Excellent repigmentation was observed in 30% cases. Improvement was significantly higher in lesions present on the head and neck. Mucosal vitiligo also showed good to excellent response. No severe side effects were reported. No complications or recurrences were observed during the follow-up period.  Conclusion: Combination of microneedling and tacrolimus was found to be safe and efficacious in the treatment of stable vitiligo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Introdução:  O vitiligo é uma doença amelanótica que pode se manifestar como manchas localizadas até quase à despigmentação total. É considerada uma doença cosmética, mas é acompanhada por extensos efeitos psicológicos. Vários tratamentos foram tentados até agora, mas nenhum método atingiu a resposta desejada. O tacrolimus é um agente frequentemente usado para o tratamento do vitiligo com um perfil mínimo de efeitos colaterais. O microagulhamento é uma modalidade mais recente de ferimento terapêutico que aumenta a absorção de fármacos. A combinação de microagulhamento e tacrolimus tem sido tentada para melhorar a resposta de repigmentação no vitiligo. Nosso objetivo foi avaliar a segurança e eficácia desta modalidade combinada.  Métodos:  Quarenta pacientes foram submetidos à combinação de tacrolimus 0,1% pomada e microagulhamento em intervalos de 2 semanas por um máximo de 10 sessões com um período de acompanhamento de 6 meses. A avaliação foi baseada na graduação de repigmentação e melhora clínica de acordo com a escala de perceptibilidade do vitiligo.  Resultados:  Excelente repigmentação foi observada em 30% dos casos. A melhora foi significativamente maior nas lesões presentes na cabeça e pescoço. O vitiligo mucoso também mostrou boa a excelente resposta. Não foram relatados efeitos colaterais graves. Nenhuma complicação ou recorrência foi observada durante o período de acompanhamento.  Conclusão:  A combinação de microagulhamento e tacrolimus é considerada segura e eficaz no tratamento do vitiligo estável. Compreender e estudar o risco de infeção na utilização de terapêutica imunossupressora permite a sua aplicação de forma mais informada e segura.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Dry Needling]]></kwd>
<kwd lng="en"><![CDATA[Tacrolimus]]></kwd>
<kwd lng="en"><![CDATA[Vitiligo.]]></kwd>
<kwd lng="pt"><![CDATA[Agulhamento Seco]]></kwd>
<kwd lng="pt"><![CDATA[Tacrolimus]]></kwd>
<kwd lng="pt"><![CDATA[Vitiligo.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahajan]]></surname>
<given-names><![CDATA[VK]]></given-names>
</name>
<name>
<surname><![CDATA[Vashist]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chauhan]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[KIS]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinico-Epidemiologi-cal Profile of Patients with Vitiligo A Retrospective Study from a Tertiary Care Center of North India]]></article-title>
<source><![CDATA[Indian Dermatol Online J]]></source>
<year>2019</year>
<volume>10</volume>
<page-range>38-44</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arora]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Kumaran]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathogenesis of vitiligo An update]]></article-title>
<source><![CDATA[Pigment Int]]></source>
<year>2017</year>
<volume>4</volume>
<page-range>65-77</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sehgal]]></surname>
<given-names><![CDATA[VN]]></given-names>
</name>
<name>
<surname><![CDATA[Srivastava]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vitiligo compendium of clinico-epidemiological features]]></article-title>
<source><![CDATA[Indian J Dermatol Venereol Leprol]]></source>
<year>2007</year>
<volume>73</volume>
<page-range>149-56</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[XD]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of tarcrolimus cream 0 1% in the treatment of vitiligo]]></article-title>
<source><![CDATA[Int J Dermatol]]></source>
<year>2009</year>
<volume>48</volume>
<page-range>86-90</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Majid]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vitiligo Management An Update]]></article-title>
<source><![CDATA[British Journal of Medical Practitioners]]></source>
<year>2010</year>
<volume>3</volume>
<page-range>a332</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sisti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sisti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Oranges]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness and safety of topical tacrolimus monothera-py for repigmentation in vitiligo a comprehensive literature review]]></article-title>
<source><![CDATA[An Bras Dermatol]]></source>
<year>2016</year>
<volume>91</volume>
<page-range>187-95</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salloum]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bazzi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Maalouf]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Habre]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Microneedling in vitiligo A systematic review]]></article-title>
<source><![CDATA[Dermatol Ther]]></source>
<year>2020</year>
<volume>17</volume>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yadav]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Microneedling Advances and widening horizons]]></article-title>
<source><![CDATA[Indian Dermatol Online J]]></source>
<year>2016</year>
<volume>7</volume>
<page-range>244-54</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Savant]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surgical therapy of vitiligo Current status]]></article-title>
<source><![CDATA[Indian J Dermatol Venereol Leprol]]></source>
<year>2005</year>
<volume>71</volume>
<page-range>307-10</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ebrahim]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Elkot]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Albalate]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combined microneedling with tacrolimus vs ta-crolimus monotherapy for vitiligo treatment]]></article-title>
<source><![CDATA[J Dermatolog Treat]]></source>
<year>2020</year>
<volume>10</volume>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mina]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Elgarhy]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Saeid]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ibrahim]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison between the efficacy of micronee-dling combined with 5-fluorouracil vs microneedling with tacrolimus in the treatment of vitiligo]]></article-title>
<source><![CDATA[J Cosmet Dermatol]]></source>
<year>2018</year>
<volume>17</volume>
<page-range>744-51</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ebrahim]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Albalate]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of microneedling combined with tacrolimus versus ei-ther one alone for vitiligo treatment]]></article-title>
<source><![CDATA[J Cosmet Dermatol]]></source>
<year>2020</year>
<volume>19</volume>
<page-range>855-62</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Passeron]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ostovari]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zakaria]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Fontas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Larrouy]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Lacour]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Topical tacrolimus and the 308-nm excimer laser a synergistic combination for the treatment of vitiligo]]></article-title>
<source><![CDATA[Arch Dermatol]]></source>
<year>2004</year>
<volume>140</volume>
<page-range>1065-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nisticò]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chiricozzi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Saraceno]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Schipani]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chimenti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vitiligo treatment with mono-chromatic excimer light and tacrolimus results of an open randomized controlled study]]></article-title>
<source><![CDATA[Photomed Laser Surg]]></source>
<year>2012</year>
<volume>30</volume>
<page-range>26-30</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fai]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cassano]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Vena]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo a review of 110 patients]]></article-title>
<source><![CDATA[J Eur Acad Dermatol Venereol]]></source>
<year>2007</year>
<volume>21</volume>
<page-range>916-20</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhuvana]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sarala]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of 0 1% tacrolimus ointment in localized vitiligo: an open uncontrolled trial]]></article-title>
<source><![CDATA[Indian J Dermatol]]></source>
<year>2011</year>
<volume>56</volume>
<page-range>445-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
